MedPath

Mellow Bumps RCT - Antenatal Intervention for Vulnerable Women

Not Applicable
Completed
Conditions
Pregnancy
Mental Health Wellness 1
Mother-Child Relations
Registration Number
NCT01590212
Lead Sponsor
University of Glasgow
Brief Summary

The purpose of this study is to compare the effectiveness of a relationships based antenatal intervention (Mellow Bumps) against a comparison intervention (Chillout In Pregnancy) and also against the normal antenatal care which is received during pregnancy (Care As Usual). The Mellow Bumps intervention will seek to improve maternal anxiety and maternal sensitivity whilst the Chillout In Pregnancy intervention will aim to improve only maternal anxiety. This will allow the researchers to determine what type of intervention, if any, is most successful at improving the outcomes of the mother and child. This will be measured by looking at the mother's stress response, anxiety, depression and irritability, the baby's stress response and the interactions between the mother and the baby. Participants in the study will be pregnant women who would be between 20 and 30 weeks pregnant at the start of the antenatal intervention. Participants will be chosen to take part in one of the three conditions (Mellow Bumps, Chillout In Pregnancy or Care As Usual) at random. All participants will be asked to complete questionnaires and give saliva samples prior to the intervention. The questionnaires will also be repeated at the end of the intervention and at a follow up occurring eight to twelve weeks after birth. Consent will also be sought to take saliva samples from the baby before and after a routine blood test when the baby is five days old. This information will then be evaluated to establish the effectiveness of the proposed interventions.

Detailed Description

Lower than anticipated recruitment numbers have resulted in changes to the planned methodology of this trial. Firstly, participants were allocated to the three arms in groups/blocks of 6. Secondly, randomisation of the final group recruited was abandoned.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
35
Inclusion Criteria
  • pregnant, between 20 & 30 weeks gestation at start of intervention
  • Identified by midwives as meeting Special Needs in Pregnancy (SNiP) criteria
  • basic understanding of written and spoken English
Exclusion Criteria
  • not identified as vulnerable through SNiP criteria
  • less than 20 weeks or more than 30 weeks gestation at start of intervention

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Depression Measured on EPDSPost-birth (8-12 weeks postnatal)

Depression scores as measured on the EPDS post-birth (approximately 8-12 weeks postnatal)

Edinburgh Postnatal Depression Scale (EPDS): is a standardised questionnaire which generates a single score. Normal score=0-9, Borderline=10-12, Probable depression=13-30.

Anxiety, Depression and Irritability Measured on Adult Wellbeing ScalePost-birth (8-12 weeks postnatal)

Anxiety, depression and irritability measured on the Adult Wellbeing Scale post-birth (approximately 8-12 weeks postnatal)

The Adult Wellbeing scale (AWS): a validated questionnaire which generates scores in four domains - depression, anxiety, outward-directed irritability and inward-directed irritability. The sub-scales have different cut-off scores that indicate a possible problem in that area: Anxiety (normal=0-5, borderline=6-8, problem 9-15), Depression (normal=0-3, borderline=4-6, problem 7-15), Outward directed irritability (normal=0-4, borderline=5-7, problem 8-12), Inward directed irritability (normal=0-3, borderline=4-6, problem 7-12),

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

NHS Greater Glasgow & Clyde

🇬🇧

Greenock, Inverclyde, United Kingdom

NHS Ayshire & Arran

🇬🇧

Irvine, North Ayrshire, United Kingdom

NHS Greater Glasgow & Clyde
🇬🇧Greenock, Inverclyde, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.